MicroRNAs in the prognosis and therapy of colorectal cancer: From bench to bedside

doi:10.3748/wjg.v24.i27.2949

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 24, Issue 27

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (15489)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-7) series.

Item

Count

PDF

1508

WORD

283

HTML

9285

Figures (1-1)

170

Tables (1-7)

190

Sum=11436

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

718

Download

655

Sum=1373

Publishing Process of This Article

Item

Count

Browse

1043

Download

1637

Sum=2680

Jul 21, 2018 (publication date) through Apr 26, 2024

Times Cited of This Article

Times Cited (137)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Gastroenterol. Jul 21, 2018; 24(27): 2949-2973
Published online Jul 21, 2018. doi: 10.3748/wjg.v24.i27.2949

Open in New Tab Full Size Figure Download Figure

Figure 1 MicroRNA dysregulation and colorectal cancer progression. Altered expression of representative miRNAs are shown in different stages of CRC (in bold: Normal epithelium → early adenoma → late adenoma → carcinoma → metastasis). Upregulation or downregulation of miRNAs can affect signaling pathways and propel progression of CRC, leading to angiogenesis, cell invasion, metastasis and inhibition of apoptosis. APC: adenomatous polyposis coli; CRC: Colorectal cancer; KRAS: Kirsten rat sarcoma viral oncogene homolog; TP53: tumor protein p53.

Citation: To KK, Tong CW, Wu M, Cho WC. MicroRNAs in the prognosis and therapy of colorectal cancer: From bench to bedside. World J Gastroenterol 2018; 24(27): 2949-2973
URL: https://www.wjgnet.com/1007-9327/full/v24/i27/2949.htm
DOI: https://dx.doi.org/10.3748/wjg.v24.i27.2949